- Foghorn Therapeutics is cutting 40% of its workforce after Eli Lilly ends cancer drug partnership
Quartz
- Eli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster
Quartz
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
CNBC Business
- Eli Lilly's experimental weight loss drug shed 21% of body weight in diabetes trial
Quartz
- Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
CNBC Business
- Eli Lilly is partnering with China's InnoCare on a drug deal worth up to $3.35 billion
Quartz
- Novo Nordisk and Eli Lilly are being sued over weight loss drugs' link to vision loss
Quartz
- Eli Lilly is capturing 70% of new Medicare patients on weight-loss drugs, CEO says
Quartz
- Eli Lilly broke ground on a $6.5 billion Houston plant for its oral weight loss pill
Quartz
- Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
CNBC Business
- Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
CNBC Business
- Novo Nordisk is rebranding as 'Novo' to fight Eli Lilly for obesity market share
Quartz
- Eli Lilly is buying a biotech startup for nearly $3 billion to expand into autoimmune diseases
Quartz
- Eli Lilly's diabetes drug wins FDA approval to lower heart attack and stroke risk
Quartz
- Eli Lilly is launching its weight-loss pill in the U.K. as Europe's first oral option
Quartz
- Eli Lilly is reinventing the pharma business
The Economist Business